Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
|Videos|November 4, 2021
CBD and Cannabinol Could Be Potential Treatment Options as Integrative Medicine as More Research Emerges
Kaushal Nanavati, MD, assistant dean of wellness and director of integrative medicine and survivorship at the Upstate Cancer Center discusses how CBD and cannabinol can offer potential treatment options as more research is being brought to the forefront on these as integrative medicine.
Advertisement
In a Pharmacy Times® interview, Kaushal Nanavati, MD, FAAFP, ABOIM, ABIHM assistant dean of wellness and director of integrative medicine and survivorship at the Upstate Cancer Center, spoke about his 2021 NANETS presentation on the integrative management of neuroendocrine tumors.
He discussed how CBD and cannabinol can offer potential treatment options as more research is being brought to the forefront on these as integrative medicine.
Advertisement
Related to this article
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
IRAKLIA shows isatuximab OBI boosts comfort and satisfaction vs IV in multiple myeloma, enabling fast at-home dosing with strong completion.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Long-term CASSIOPEIA Registry results show that daratumumab maintenance supports sustained minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma.
A phase 1/2 analysis found rapid, deep responses with mezigdomide plus elranatamab in patients with relapsed or refractory multiple myeloma, but the small cohort and limited follow-up require cautious interpretation.
At NEIAP 2026, Kelsey Norman, PharmD, walked through how VESALIUS-CV, Lp(a)HORIZON, and CKM guidelines change pharmacist-led lipid care.
An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-quarters of treated patients.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
2
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
3
Ramantamig's 93.6% ORR and Outpatient CRS Control
4
After 180 Years, Multiple Myeloma Gets a Definition of Cure
5